Compared to patients treated with sodium-dependent glucose transporters 2 (SGLT2) inhibitors as monotherapy, those receiving GLP-1RAs for type 2 diabetes exhibited a significantly increased risk of thyroid hyperplasia and thyroid cancer [22]
It was found that the antibacterial effect depended on the match between the roughness of the GO films and the bacterial size
Hepatology (Baltimore) 78(6): 1966 [PubMed] Romano M, Vacante M, Cristaldi E, Colonna V, Gargante MP, Cammalleri L, Malaguarnera M (2008) L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin
Since GLP-1s were first approved for weight loss and the market took off, there has been significant concern about the relatively high rate of loss of lean body mass, particularly muscle, especially as compared with traditional weight loss techniques
Some of these experiences were genuine adverse reactions